To identify the correlation between existing T cell phenotypes in the peripheral blood of patients with NSCLC and their clinical response during cancer immunotherapy with PD-1/PD-L1 blockade, we conducted flow cytometry analyses of CD4+ and CD8+ T cells derived from the PBMCs of patients with NSCLC at baseline. This evidence concerns the gene CD4 and non-small cell lung carcinoma.